The effect of adalimumab on key drivers in the pathogenesis of psoriasis3. (March 2014)

• Record Type: Journal Article
• Authors: Hendriks, A.G.M.; van der, H.M.J.; Wolberink, E.A.W.; Seyger, M.M.B.; Schalkwijk, J.; Zeeuwen, P.L.J.M.; de, E.M.G.J.; Pasch, M.C.; van, P.E.J.; van de, P.C.M.
• Is Part Of: British journal of dermatology. Volume 170:Number 3(2014:Mar.)
• Page Start: 571
• Page End: 580
• Publication Date: 2014-03
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12705
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="short" xml:lang="en" id="bjd12705-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>What's already known about this topic?</bold> </p> <p> <list id="bjd12705-list-0001" list-type="bullet"> <list-item> <p>Recently introduced biologics targeting specific immune mechanisms have identified crucial steps in the pathogenesis of psoriasis.</p> </list-item> </list> </p> <p> <bold>What does this study add?</bold> </p> <p> <list id="bjd12705-list-0002" list-type="bullet"> <list-item> <p>During adalimumab treatment markers of epidermal differentiation, proliferation and the innate immune system revert rapidly to normal, well before changes in the adaptive immune system become apparent.</p> </list-item> </list> </p> </abstract>